Joint Formulary & PAD

Daridorexant - Insomnia in adults

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

On recommendation from specialist sleep clinics (locally at RSFT/QVH) only.

Documents :
 

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Daridorexant
Indication :
Insomnia in adults
Group Name :
Keywords :
Brand Names Include :
Quviviq
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Daridorexant is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Insomnia in adults.

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a change in traffic light status to BLUE (on specialist recommendation) for daridorexant for chronic insomnia.

It is important to reach the therapeutic dose of 50mg daily, however, experience shows that initiation at 25mg would be recommended to reduce the potential for side effects, but the dose must be increased to 50mg if the patient tolerates the starting dose after 2 weeks, as maximal benefit is obtained at 50mg.

Patients should be advised that the treatment with daridorexant should be used alongside the learning from CBTi and that it may take several months to reach optimum benefit.

During the use of Daridorexant, patients should be encouraged to continue implementing the taught strategies of CBTI.

Treatment may continue beyond 1 year if the patient was experiencing significant benefit, and stopping treatment gradually meant that this benefit was lost.

Discontinuation should be carried out slowly, reducing to 25mg before stopping.